Table 1.

Correlation of IL22+ cell density with clinicopathologic features in n = 425 colorectal cancer specimens.

IL22 lowIL22 high
CharacteristicsN = 221(100%)N = 204(100%)Pa
Age
 Years (median, mean)71, 69.5(40–90)71, 70.5(40–96)P = 0.318
Sex
 Female117(52.9)104(51.0)P = 0.687
 Male104(47.1)100(49.0)
Diameter
 mm (median, mean)50, 52.4(10–170)50, 51.0(7–160)P = 0.527
Tumor location
 Left sided136(61.5)138(67.6)P = 0.167
 Right sided85(38.5)65(31.9)
Histologic subtype
 Mucinous9(4.1)19(9.3)P = 0.494
 Nonmucinous212(95.9)185(90.7)
pT stage
 pT17(3.2)8(3.9)P = 0.043b
 pT226(11.8)32(15.7)
 pT3140(63.3)138(67.6)
 pT439(17.6)21(10.3)
pN stage
 pN099(44.8)112(54.9)P = 0.059c
 pN164(29.0)51(25.0)
 pN248(21.7)35(17.2)
Tumor grade
 G17(3.2)2(1.0)P = 0.255
 G2193(87.3)185(90.7)
 G311(5.0)12(5.9)
Vascular invasion
 Absent150(67.9)155(76.0)P = 0.099
 Present62(28.1)44(21.6)
Tumor border
 Pushing54(24.4)64(31.4)P = 0.151
 Infiltrating156(70.6)135(66.2)
PTL inflammation
 Absent167(75.6)145(71.1)P = 0.162
 Present45(20.4)54(26.5)
Microsatellite stability
 Deficient30(13.6)33(16.2)P = 0.452
 Proficient191(86.4)171(83.8)
5-year survival rate
(95% CI)0.430.36–0.500.580.51–0.65P = 0.004
  • Abbreviations: CI, confidence interval; PTL, peritumoral lymphocytic.

  • aCorrelation between the IL22-low and IL22-high subgroup. Percentage may not add to 100% due to missing values of some variables.

  • bOverall difference in subgroup analysis due to T4.

  • cOverall difference in subgroup analysis due to N0.